VaramirStart free · no cardSign in
NTLA as of Nov 1 · 08:56 ET
NTLANasdaqIn Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc. · Brief

Next report

4 days

Nov 5 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
3 of 8≥ implied
avg implied
±13.7%
avg realized
±8.0%
Jan 10 '25±10.4%▼−15.14%×1.46
Feb 27 '25±16.1%▲+0.56%×0.03
May 8 '25±11.6%▲+13.58%×1.17
Aug 7 '25±14.0%▲+0.79%×0.06
Q3 FY25±18.9%▼−22.73%×1.20
Q1 FY26±18.7%▲+6.41%×0.34
May 11 '26±7.2%▲+2.34%×0.33
Q2 FY26±12.8%▲+2.46%×0.19
quarterimplied−25%0+25%realized×
Q2 FY26±12.8%▲+2.46%×0.19
May '26±7.2%▲+2.34%×0.33
Q1 FY26±18.7%▲+6.41%×0.34
Q3 FY25±18.9%▼−22.73%×1.20
Aug '25±14.0%▲+0.79%×0.06
May '25±11.6%▲+13.58%×1.17
2 older reports
Feb '25±16.1%▲+0.56%×0.03
Jan '25±10.4%▼−15.14%×1.46
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · est.

Bull2

5disclosed supplier and customer ties in SEC filingsSEC filings
+23.01%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

Bear2

1.92%of ARK Innovation ETF's assets, the largest tracked-fund weightN-PORT · Jul 31 '26
3 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

NTLA report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 22impliedImplied move: ±15.4% into Nov 5 earnings (Oct 22 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.